Search: onr:"swepub:oai:lup.lub.lu.se:b5758794-634a-4c4e-8c78-8172388a72f1" >
Incidence of Cancer...
Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial.
- Article/chapterEnglish2014
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:b5758794-634a-4c4e-8c78-8172388a72f1
-
https://lup.lub.lu.se/record/4738759URI
-
https://doi.org/10.1016/j.amjcard.2014.08.016DOI
-
https://gup.ub.gu.se/publication/203715URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) clinical trial, including 1,873 patients found an increased risk for cancer with lipid-lowering therapy with ezetimibe/simvastatin 10/40 mg/day, relative to placebo. In a registry-based follow-up study over 21 months from the conclusion of the SEAS trial, new incident cancer and total mortality were investigated in the SEAS study cohort from Denmark, Finland, Norway, Sweden, and the United Kingdom. Among 1,359 subjects eligible for follow-up (73% of the original total cohort), 1,194 had no history of cancer (primary follow-up cohort). New cancers and deaths were identified in the national cancer and mortality registries and classified by an Expert Review Committee. Data were analyzed using Cox proportional-hazards models of new cancers and mortality during follow-up according to treatment group assigned in the SEAS base study and with age, gender, smoking history, and previous cancers as covariates. The primary follow-up cohort had 12 patients with new cancers in the ezetimibe/simvastatin group and 22 in the placebo group (hazard ratio 0.55, 95% confidence interval 0.27 to 1.11), indicating no significant difference between the treatment groups. During follow-up, 43 patients assigned to ezetimibe/simvastatin and 33 assigned to placebo died (hazard ratio 1.29, 95% confidence interval 0.82 to 2.03). In conclusion, in this registry-based observational follow-up study of the original SEAS study patient population, treatment with ezetimibe/simvastatin was not associated with an increased risk for cancer or mortality in the 21-month period after the completion of the original SEAS study.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ramey, Dena Rosen
(author)
-
Emneus, Martha
(author)
-
Iachina, Maria
(author)
-
Stavem, Knut
(author)
-
Bolin, KristianGothenburg University,Göteborgs universitet,Centrum för hälsoekonomi (CHEGU),Centre for Health Economics(Swepub:gu)xbolkr
(author)
-
McNally, Richard
(author)
-
Busch-Sørensen, Michael
(author)
-
Willenheimer, RonnieLund University,Lunds universitet,Kardiologiska klinikens forskargrupp,Forskargrupper vid Lunds universitet,Cardiology Research Group,Lund University Research Groups(Swepub:lu)medf-rw0
(author)
-
Egstrup, Kenneth
(author)
-
Kesäniemi, Y Antero
(author)
-
Ray, Simon
(author)
-
Basta, Nermine
(author)
-
Kent, Christi
(author)
-
Pedersen, Terje R
(author)
-
Göteborgs universitetCentrum för hälsoekonomi (CHEGU)
(creator_code:org_t)
Related titles
-
In:American Journal of Cardiology: Elsevier BV114:10, s. 1518-15221879-19130002-9149
Internet link
Find in a library
To the university's database
- By the author/editor
-
Green, Anders
-
Ramey, Dena Rose ...
-
Emneus, Martha
-
Iachina, Maria
-
Stavem, Knut
-
Bolin, Kristian
-
show more...
-
McNally, Richard
-
Busch-Sørensen, ...
-
Willenheimer, Ro ...
-
Egstrup, Kenneth
-
Kesäniemi, Y Ant ...
-
Ray, Simon
-
Basta, Nermine
-
Kent, Christi
-
Pedersen, Terje ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Health Sciences
-
and Health Care Serv ...
- Articles in the publication
-
American Journal ...
- By the university
-
Lund University
-
University of Gothenburg